Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.

ABSTRACT:

Background

Capecitabine and paclitaxel are established effective treatments, alone and combined with other cytotoxic and targeted agents, for metastatic breast cancer (MBC). Paclitaxel polyglumex (a macromolecular conjugate of paclitaxel bound to poly-L-glutamic acid) has potential advantages over conventional paclitaxel, including little alopecia, short infusion time with no premedication, enhanced tumor permeability/retention effect, and improved tolerability. We therefore examined tolerability and efficacy of paclitaxel polyglumex with capecitabine in patients with MBC.

Patients and methods

This was a single-stage phase 2 study, with interim analysis conducted with endpoints of tumor response, adverse events (toxicities), time to progression, and overall survival. The mai

SUBMITTER: Northfelt DW 

PROVIDER: S-EPMC3593738 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature